Powder and dose presentation
Particle properties, blend behaviour, moisture sensitivity and dose format influence product and process strategy.
THROUGH LIROK PHARMA
Dry Powder Inhalers
Specialized DPI manufacturing capability within the integrated pharmaceutical ecosystem, complementing Jean Vichar’s MDI and nasal spray platforms.
REF. JV-DPI-001ECOSYSTEM CAPABILITY
Dry powder inhaler capability through Lirok Pharma.
Within the integrated pharmaceutical ecosystem, Lirok Pharma provides the group’s specialized dry powder inhaler manufacturing capability. This complements Jean Vichar’s metered dose inhaler and nasal spray platforms.
DPI opportunities are evaluated according to formulation and powder characteristics, device configuration, analytical requirements, documentation status and the intended commercialization pathway. Project scope is coordinated with the relevant Lirok and Jean Vichar teams.
Specialized respiratory focusDPI manufacturing is positioned as a distinct capability rather than an extension of liquid or pressurized platforms.
Formulation and device alignmentPowder properties, dose presentation and device configuration must be evaluated together.
Technology transferAvailable knowledge, methods, components and process history are reviewed before transfer activities are defined.
Integrated partnership accessPartners can discuss DPI within the wider ecosystem’s sourcing, development and commercialization context.
REF. JV-DPI-002PROJECT CONSIDERATIONS
Device configuration
The inhaler and its dose presentation must be considered as part of the product, not as a separate packaging decision.
Analytical and regulatory package
Methods, specifications, performance data and technical documentation determine readiness for transfer and registration support.
REF. JV-DPI-003HOW TO ENGAGE
One entry point to a broader respiratory manufacturing ecosystem.
A DPI inquiry can begin with Jean Vichar and be coordinated with Lirok Pharma according to technical scope.
Initial discussions should identify the product’s development stage, formulation and device status, available documentation, target market and desired commercial milestone. This allows the appropriate technical team to define the next review.
No ownership percentage or unsupported facility claim is required to explain this capability. Lirok Pharma is presented as a group company and the ecosystem’s DPI specialist.